Back to Search Start Over

1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug

Authors :
Vermathen, Martina
Paul, Lydia E H
Diserens, Gaëlle
Vermathen, Peter
Furrer, Julien
Source :
PLoS ONE, PLoS ONE, Vol 10, Iss 5, p e0128478 (2015), Vermathen, Martina; Paul, Lydia E H; Diserens, Gaëlle; Vermathen, Peter; Furrer, Julien (2015). 1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug. PLoS ONE, 10(5), e0128478. Public Library of Science 10.1371/journal.pone.0128478
Publication Year :
2015
Publisher :
Public Library of Science, 2015.

Abstract

(1)H high resolution magic angle spinning (HR-MAS) NMR spectroscopy was applied in combination with multivariate statistical analyses to study the metabolic response of whole cells to the treatment with a hexacationic ruthenium metallaprism [1](6+) as potential anticancer drug. Human ovarian cancer cells (A2780), the corresponding cisplatin resistant cells (A2780cisR), and human embryonic kidney cells (HEK-293) were each incubated for 24 h and 72 h with [1](6+) and compared to untreated cells. Different responses were obtained depending on the cell type and incubation time. Most pronounced changes were found for lipids, choline containing compounds, glutamate and glutathione, nucleotide sugars, lactate, and some amino acids. Possible contributions of these metabolites to physiologic processes are discussed. The time-dependent metabolic response patterns suggest that A2780 cells on one hand and HEK-293 cells and A2780cisR cells on the other hand may follow different cell death pathways and exist in different temporal stages thereof.

Details

Language :
English
Database :
OpenAIRE
Journal :
PLoS ONE, PLoS ONE, Vol 10, Iss 5, p e0128478 (2015), Vermathen, Martina; Paul, Lydia E H; Diserens, Ga&#235;lle; Vermathen, Peter; Furrer, Julien (2015). 1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug. PLoS ONE, 10(5), e0128478. Public Library of Science 10.1371/journal.pone.0128478 <http://dx.doi.org/10.1371/journal.pone.0128478>
Accession number :
edsair.doi.dedup.....64af6dee9e9c7912b9064832bf0fdcf7
Full Text :
https://doi.org/10.7892/boris.69838